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MicroRNAs are abundantly present and surprisingly stable in multiple biological ﬂuids.
These ﬁndings have been followed by numerous reverse transcription real-time quantitative
PCR (RT-qPCR)-based reports revealing the clinical potential of using microRNA levels
in body ﬂuids as a biomarker of disease. Despite a rapidly increasing body of literature,
the ﬁeld has failed to adopt a set of standardized criteria for reporting the methodology
used in the quantiﬁcation of cell-free microRNAs. Not only do many studies based on
RT-qPCR fail to address the Minimum Information for Publication of Quantitative Real-Time
PCR Experiments (MIQE) criteria but frequently there is also a distinct lack of detail in
descriptions of sample source and RNA isolation. As a direct result, it is often impossible
to compare the results of different studies, which in turn, hinders progress in the ﬁeld. To
address this point, we propose a simple set of criteria to be used in conjunction with MIQE
to reveal the true potential of cell-free microRNAs as biomarkers.
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INTRODUCTION
In recent years, a number of studies have shown that cell-free
microRNAs are readily detectable in body ﬂuids, such as plasma
or serum. The surprising stability of cell-free microRNAs in these
body ﬂuids has been attributed to encapsulation of microRNAs in
microvesicles such as exosomes (Cortez and Calin, 2009; Kosaka
et al., 2010), and association with protein complexes, like high
density lipoproteins (Vickers et al., 2011) and argonaute 2 (Arroyo
et al.,2011; Turchinovich et al.,2011). Theseﬁndings led tonumer-
ous studies aiming at the identiﬁcation of microRNAs, mainly
in plasma and serum, as potential diagnostic and/or prognostic
markers for a variety of diseases (Reid et al., 2011; Creemers et al.,
2012; Mo et al., 2012). However, although most studies are using
reverse transcription real-time quantitative PCR (RT-qPCR) for
detection of microRNAs, there is still a lack of consensus regarding
isolation procedures, optimal quantiﬁcation methods, reference
genes, and quality control of samples. In addition, most studies
fail to provide sufﬁcient detail on the methods used for RNA iso-
lation, quality control of samples, and do not report according
to Minimum Information for Publication of Quantitative Real-
Time PCR Experiments (MIQE) criteria (Bustin et al., 2009). As
a result, comparisons between studies from different laboratories
are almost impossible, and it is not surprising that different studies
using proﬁling strategies to identify plasma/serum biomarkers for
the same disease fail to identify the same microRNAs.
In order to overcome these problems, we propose a simple set
of reporting criteria to be used in conjunction with MIQE report-
ing guidelines (Bustin et al., 2009). The following sections outline
the steps undertaken to quantify cell-free microRNAs together
with important aspects to be considered in each step. We limit the
microRNA quantiﬁcation section to RT-qPCR as this is the most
commonly used method for microRNA detection, and for sim-
plicity we focus on plasma and serum, but many aspects will apply
equally to other quantiﬁcation methods (such as microarray)
or other biological ﬂuids. Finally, we provide lists of important
points to be included when reporting investigation of cell-free
microRNAs.
SAMPLE COLLECTION
The ﬁrst critical step in the process of assessing levels of cell-free
microRNAs in plasma and serum is the collection and handling
of the sample. Both serum and plasma are suitable for assess-
ment of cell-free microRNAs, but when using plasma samples
ethylenediaminetetraacetic acid (EDTA) or citrate are the pre-
ferred anticoagulants as heparin is known to inhibit both reverse
transcription and qPCR steps (Kroh et al., 2010). The use of more
than one type of collection tubewithin a study is generally discour-
aged as the resultingmicroRNAproﬁles can vary between different
tubes,making comparisons inaccurate (Kroh et al., 2010). Reports
on cell-free microRNAs should therefore always include details
regarding the blood collection procedure, type of blood collection
tube, and processing of the sample.
Essential information to be provided:
– Collection site, caliber, and type of needle/cannula
– Type and size of collection tube (including manufacturer)
– Time between collection and further processing
– In case of serum, time allowed for clotting
– Conditions of sample processing (centrifugation speed and
time)
– Storage condition of samples
QUALITY CONTROL OF SAMPLES
One of the most critical points in the process of quantifying cell-
free microRNAs is that of quality assurance and quality control
(QA/QC). While being neglected in the early stages of cell-free
microRNA research, a small number of studies have now shown
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that the contamination with microRNAs released from circulat-
ing blood cells represents one of the major sources of microRNAs
detectable in plasma or serum (Kirschner et al., 2011; McDon-
ald et al., 2011; Pritchard et al., 2012). The most common source
of blood cell derived microRNAs are red blood cells (RBCs) and
two studies have shown that hemolysis occurring during sam-
ple collection or processing can signiﬁcantly alter the levels of
certain RBC-enriched microRNAs, such as miR-16 and miR-
451 (Kirschner et al., 2011; McDonald et al., 2011). In addition,
microRNAs released from platelets can also alter the microRNA
proﬁle (Pritchard et al., 2012). These changes caused by rupturing
of blood cells result in variation in microRNA levels independent
of the presence or absence of a certain disease state. While not
yet investigated in detail, one can conﬁdently assume that other
microRNAs, including those previously being proposed as poten-
tial biomarkers for disease can be affected in a similar way to,
e.g., miR-16 and miR-451. Measuring the degree of hemolysis, a
major source of blood cellmicroRNAs in the ﬂuid component, can
be easily achieved by assessing the presence of free hemoglobin
through simple measurement of the absorbance at 414 nm (the
absorbancemaximum of free hemoglobin) in the initial plasma or
serum sample using a standard spectrophotometer (Wong et al.,
2006). Data on the degree of hemolysis of samples should always
be provided, and applying a cut-off level of free hemoglobin to
determine if samples are usable for further analysis, such as an
OD414 of 0.2 as we have suggested (Kirschner et al., 2011), should
always be considered. In addition, like for formalin-ﬁxed parafﬁn-
embedded (FFPE) tissue samples (Szafranska et al., 2008), the age
of a sample will certainly play a role in respect to the quality of
RNA that can be obtained (Grasedieck et al., 2012). Both storage
condition and sample age should therefore be provided.
RNA ISOLATION
The isolation of RNA represents another critical step in order to
obtain a sample of acceptable quality for further investigation. The
most commonly used methods for RNA isolation from body ﬂu-
ids are (i) column-based puriﬁcation with mostly mirVana PARIS
and Qiagen (miRNeasy Serum/Plasma Kit) or (ii) non-column
puriﬁcation using reagents such as TRIzol LS or QIAzol. While
no study has yet shown a direct comparison between column-
based and non-column puriﬁcation, a study in cell lines suggests
that care must be taken regarding the choice of isolation method.
Kim et al. (2012) have shown that when isolating RNA from cells
using a non-column method the number of cells seems to not
only affect the efﬁciency of RNA isolation in general, but also
result in a selective loss of microRNAs with low guanine–cytosine
(GC) content when isolating from a small cell number, hence
when handling samples with low RNA concentration. Plasma and
serum are low RNA concentration samples, raising the possibil-
ity that preferential isolation of a subset of microRNAs might
occur too when using non-column puriﬁcation. In addition, data
from our own studies generally comparing TRIzol LS and mir-
Vana PARIS isolation efﬁciencies have shown that while TRIzol LS
puriﬁcation results in higher levels of total RNA recovered from
plasma samples (Figure 1A), mirVana PARIS is superior in isolat-
ing small RNAs as shown for both moderately to highly abundant
endogenous microRNAs (Figure 1B), and exogenous spike-ins
(Figure 1C). Nevertheless, as no formal comparison for larger
numbers of microRNAs has been performed so far for plasma
and serum, no ﬁrm conclusions can be drawn regarding the best
isolation method for these sample types.
Regardless of the relative merits of the various options for RNA
isolation, studies investigating cell-free microRNAs should always
provide sufﬁcient details on the isolation method used, and these
should be:
– Sample volume from which RNA was isolated
– Reagent or kit used for RNA isolation
– Whether a carrier (glycogen, tRNA, etc.) was used, the concen-
tration of any such reagent and at which step of the isolation
they have been added
– Whether and in which concentration any spike-ins such as syn-
thetic C. elegans microRNAs have been used and at which step
of the isolation process those have been added
– The volume used for resuspension or elution of the ﬁnal RNA
sample.
RNA QUANTIFICATION
Quantiﬁcation of RNA isolated from dilute samples such as
plasma/serum can be very difﬁcult (Kroh et al., 2010). Even when
using a carrier to enhance the isolation efﬁciency, attempts tomea-
sure RNA concentration by standard spectrophotometry often fail
due to the detection limit of this method (generally around 4–
10 ng/μl). Alternatively ﬂuorometric quantitation can be used,
however, especially when using serum the concentration of the
obtained samples can still be too low for accurate quantitation.
Using larger sample input into the isolation processmay overcome
this problem. However, large amounts of sample are not always
available and most studies have shown that microRNAs are read-
ily detectable when isolating from 500 μl or less of plasma/serum
(Kroh et al., 2010).
As a consequence of these difﬁculties in quantifying the RNA
concentration of dilute solutions, it is in many cases not possi-
ble to use equal amounts (e.g., nanogram) of template RNA for
each sample in the subsequent reverse transcription step. Often
the only alternative is to use equal input volume of RNA (Mitchell
et al., 2008), but this approach requires the availability of an alter-
native normalization method to account for differences in input
RNA concentration. The most commonly used approaches here
are the use of an exogenous spike-inmicroRNAof known quantity
(Mitchell et al., 2008) or the use of endogenous control micro-
RNAs which do not vary signiﬁcantly between samples obtained
from study and control subjects (Kirschner et al., 2011). However,
both these strategies are associated with further problems which
are discussed in more detail below.
REVERSE TRANSCRIPTION REAL-TIME QUANTITATIVE PCR
A number of different technologies are available for RT-qPCR
quantiﬁcationofmicroRNAs. Themost commonlyused technolo-
gies are the microRNA-speciﬁc stem-loop reverse transcription
in combination with TaqMan qPCR primer/probe assays (Life
Technologies) or the combination of poly-A-tailing in the reverse
transcription step followed by either locked-nucleic-acid (LNA)-
enhanced forward and reverse primers (Exiqon) or standard SYBR
green forward and reverse primers (Qiagen). Each technology
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FIGURE 1 | Comparison betweenTRIzol LS and mirVana PARIS
microRNA isolation efficiency.Total RNA was isolated from 500 μl plasma
from three healthy volunteers and total RNA concentration (A), levels of
moderately to highly abundant endogenous microRNAs (B), and of
exogenous spike-ins (C) were assessed. RT-qPCR data are presented as raw
Cq values.
provides advantages and disadvantages, but the superiority of one
system over the other has not been proven (Zampetaki and Mayr,
2012). When reporting on RT-qPCR for cell-free microRNAs it is
therefore essential to provide sufﬁcient detail (following theMIQE
guidelines; Bustin et al., 2009) to allow the reader to understand
and reproduce published data using the same technology.
The minimum details that should be provided are:
– Primer sequences or exact assay IDs/catalog numbers when
using proprietary assays
– Amount of RNA used as input into reverse transcription, or
volume of eluate
– Reverse transcription procedure (poly-A-tailing or stem-loop)
including all reagents and concentrations used, and reaction
conditions (even if as per manufacturer)
– Details of instrument used to perform reverse transcription
– Whether preampliﬁcation was done, and if so how
– Dilution of cDNA and amount of cDNA used in qPCR
– All reagents and the concentrations used for qPCR as well as
reaction conditions
– Details on instrument used to run qPCR and methods used to
determine threshold (details on software used to analyze qPCR
data/determine threshold)
NORMALIZATION OF RT-qPCR DATA
The ﬁnal and perhaps most critical step when quantifying cell-
free microRNAs is the quantiﬁcation or normalization method
used. With the amount of RNA isolated from plasma or serum
being very low and even with the use of carrier reagents during
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FIGURE 2 | Summary of details that should be provided when reporting on cell-free microRNAs.
RNA isolation often below the threshold of detection (at least
for standard spectrophotometry), it is frequently not possible to
normalize the concentration of RNA used for reverse transcrip-
tion. Equal volumes of input RNA are therefore often used instead
of a ﬁxed concentration; however this approach introduces the
variable associated with comparing samples of unknown RNA
concentration.
The major strategies proposed to overcome these problems are
(i) the use of endogenous control microRNAs for normalization
(Kirschner et al., 2011), (ii) the use of known quantities of exoge-
nous microRNAs (mainly C. elegans miRs) that are spiked-in to
compensate for differences in isolation efﬁciency (Mitchell et al.,
2008; Kroh et al., 2010), and (iii) absolute quantiﬁcation based on
standard curves generated from synthetic microRNAs.
While an absolute quantiﬁcation would most likely be the pre-
ferred measurement for a clinical setting, the variability in RNA
input into the reverse transcription still leaves the problem of
normalization between different samples.
Measurement of microRNAs spiked-in during the process of
RNA isolation has the potential to account for the variability in
initial RNA concentration. However, these spiked-in oligos do not
account for variability caused by ruptured blood cells (Kirschner
et al., 2011; McDonald et al., 2011; Pritchard et al., 2012). As dis-
cussed above, the quality of a sample, in particular the degree of
hemolysis can have substantial impact on the levels of microRNAs
measured in plasma or serumand should therefore always be taken
into consideration. Spiked-in microRNAs are not suited to be
used as a second quality control step, like miR-16 or miR-451
are, and one should therefore be careful when using only those
as normalization controls for qPCR data. Nevertheless, if spiked-
in oligos are used then more information should be provided,
including some indication of recovery (%) and variation between
samples.
Endogenous microRNAs such as miR-16 and miR-451 are
among the most abundant microRNAs present in plasma. These
microRNAs represent suitable candidates for normalization of
qPCR data. However, as it is not known yet if other micro-
RNAs are also affected by hemolysis, one cannot use miR-16
and miR-451 to adjust for varying degrees of hemolysis in dif-
ferent samples. A detailed analysis of the microRNA proﬁles
in non-hemolyzed and hemolyzed samples is required to deter-
mine which microRNAs are affected by rupturing of RBCs. This
exercise may help us to deﬁne subsets of microRNAs that are
affected by hemolysis in the same way, thereby allowing a combi-
nation of endogenous control and biomarkers microRNA(s) to be
selected. Independent of the outstanding problems associated
with the sample quality’s effect on cell-free microRNAs, an addi-
tional problem with many studies currently being published
is a lack of detail regarding the exact ways of normalization
and calculation of relative abundance levels of microRNAs.
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Studies reporting on cell-free microRNAs should provide the
following details:
– Whether a ﬁxed volume or a ﬁxed RNA concentration was used
as input into reverse transcription
– Whether a spiked-in microRNA(s) was used, and if so how
many and the exact concentration added during the isolation
procedure
– If spiked-in microRNAs were used, at least the average recovery
of those should be reported
– In case of normalization to a spiked-in microRNA or endoge-
nous control, details on the normalization procedure should be
provided (equations used)
– In case of reporting relative expression in one group as com-
pared to another group, details on the calculations should be
provided (2−Cq; Livak and Schmittgen, 2001; Schmittgen
and Livak, 2008) is often not detailed enough – how exactly was
Cq calculated?)
– Raw data should be provided
CONCLUSION/PERSPECTIVE
Since their discovery, cell-free microRNAs have been quickly
introduced as potential biomarkers. However, it is important to
bear in mind that the ﬁeld of cell-free microRNA research is still
in its infancy and that a lack of standardized reporting is mak-
ing comparisons between studies as well as reproducibility of
published data in independent sample series virtually impossi-
ble. While we have not solved all the problems associated with
quantiﬁcation of cell-free microRNAs, such as the most appropri-
ate normalization strategies or whether samples with hemolysis
can/should be used for analysis, the ﬁeld would certainly ben-
eﬁt from a standardized way of reporting as summarized in
Figure 2. Standardized reporting will allow researchers to bet-
ter understand the data obtained in different laboratories and
to use the same methods for potential follow-up or validation
studies. Single discovery studies are unlikely to result in the
discovery of novel biomarkers for clinical use and it is impor-
tant to provide all the details of the methodology used to allow
further validation by independent investigators. Only in this
way the ﬁeld is enabled to advance eventually leading to the
implementation of novel microRNA-based diagnostic/prognostic
tests.
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